当前位置:肿瘤瞭望>(WCLC)世界肺癌大会>正文

[WCLC2016]上海市肺科医院展示多项临床研究成果

作者:肿瘤瞭望   日期:2016/12/5 10:29:34  浏览量:23966

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

在历届WCLC会议中,今年是中国学者表现最亮眼的一次。上海市肺科医院带来了大量的高质量临床研究,以口头报告、壁报交流的形式展现了研究成果,在Meeting the Expert Session和Scientific Session等专场也有他们的身影。详情如下。

  在历届WCLC会议中,今年是中国学者表现最亮眼的一次。上海市肺科医院带来了大量的高质量临床研究,以口头报告、壁报交流的形式展现了研究成果,在Meeting the Expert Session和Scientific Session等专场也有他们的身影。详情如下。
 
  主题报告(Keynote speech)
 
  周彩存
 
  讲题:SC05.03 novel tyrosine kinase inhibitors in lung cancer
 
  专场:SC05: Novel drugs in thoracic cancer
 
  时间:12月5日11:40-12:00
 
  地点: C2
 
  WCLC专场主持(Chair of session)
 
  周彩存教授在12月7日担任PL04a: Immune checkpoint inhibitors in advanced NSCLC和ED11: Advanced NSCLC:State–of–the–Art Treatment专场的主持。
 
  专家面对面专场(Meet the expert session)
 
  李雪飞
 
  讲题:MET21.01: Next generation sequencing
 
  专场:Meet the Expert (MTE21)
 
  时间:12月7日07:30 - 08:30
 
  地点:Schubert 1
 
  口头报告(Oral presentation)
 
  任胜祥
 
  MA04.03: Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC
 
  专场:MA04: HER2, P53, KRAS, and other targets in advanced NSCLC
 
  时间: 12月5日16:12-16:18
 
  地点:Lehar 3-4
 
  赵沙
 
  OA11.07: Combining Apatinib and anti-PD-L1 antibody Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer
 
  专场:OA11: Angiogenesis in advanced lung cancer
 
  时间:12月6日12:05-12:15
 
  地点:Stolz 2
 
  蔡薇菁
 
  MA15.03: The predictive value of mutation/neoantigen burden from ctDNA on the efficacy of PD-1 blockade in advanced NSCLC
 
  专场:MA15: Immunotherapy prediction
 
  时间:12月7日14:32-14:38
 
  地点: Schubert 1
 
  壁报交流(Poster presentation)
 
  周彩存
 
  ●P2.06-013: Afatinib in Patients with Advanced HER2 Mutation-Positive (M+) NSCLC Previously Treated with Chemotherapy
 
  ●P3.02b-096: Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results
 
  李雪飞
 
  ●P3.02b-104: Rebiopsy for patients with non-small cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitors failure
 
  苏春霞
 
  ●P2.03b-092: Predictive and Prognostic Effect of Circulating Tumor Cells in Non-small cell lung Cancer treated with targeted therapy
 
  ●P1.07–031: Clinical Evaluation of Folate Receptor–Positive Circulating Tumor Cells Detection in Patients with Small Cell Lung Cancer
 
  吴凤英
 
  ●P3.02c–025: Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer
 
  张洁
 
  ●P2.03b–032: The Peculiar Changing Pattern of Serum NSE Acts as an Indicator of Transformation from Adenocarcinoma to SCLC
 
  倪健
 
  ●P2.05–028: Comparison of Adjuvant Chemotherapy with or without Radiotherapy in NSCLC Patients with Stage IIIA–Single Station N2
 
  蒋涛
 
  ●P3.02b–075: Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients
 
  ●P3.02b–076: Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases
 
  ●P3.02b–091: Liver Metastases Is the Negative Predictive Factor for First-Line EGFR TKIs Therapy in NSCLC Patients with EGFR Mutation
 
  ●P3.02c–049: Dendritic Cells Modified with Tumor–Associated Antigen Gene Demonstrate Enhanced Antitumor Effect against Lung Cancer
 
敬请期待《肿瘤瞭望》的后续报道!

版面编辑:赵丽丽  责任编辑:张彩琴

本内容仅供医学专业人士参考


WCLC 2016上海市肺科医院

分享到: 更多